Updated Monday, 5/4.
As the market approaches a new week, several initial public offerings (IPOs) are on the horizon. This week features exciting prospects from a variety of industries, offering investors a glimpse into innovation and growth potential.
Upcoming IPOs
Five IPOs are currently scheduled for the week ahead, though additional smaller companies may add to the calendar later.
HawkEye 360
HawkEye 360 (HAWK) aims to raise $400 million at a market cap of $2.7 billion. HawkEye specializes in designing and operating a constellation of small satellites that gather radio frequency data. This data is processed through proprietary signal processing and AI-enabled analytics software to detect, geolocate, classify, and track emitters. The company primarily serves sectors such as defense, intelligence, maritime security, and spectrum monitoring. HawkEye comes to market amid robust trading among competitors in the space-based signaling sector. However, it remains unprofitable and exhibits a degree of customer concentration.
Odyssey Therapeutics
Odyssey Therapeutics (ODTX) plans to raise $225 million at an $845 million market cap. The company focuses on developing targeted therapies aimed at autoimmune and inflammatory diseases. Its leading programs include oral small-molecule candidates that target the RIPK2 and SLC15A4 pathways. The most advanced drug has shown early clinical efficacy in treating ulcerative colitis, with additional treatments currently in preclinical development.
Suja Life
Suja Life (SUJA) seeks to raise $200 million at an $871 million market cap. The company offers cold-pressed juices, wellness shots, and functional sodas through its Suja Organic, Vive Organic, and Slice brands. As a leader in the cold-pressed and wellness shot categories, Suja’s vertical integration enhances its processing capabilities. However, the company carries significant debt, which has impacted its profitability.
Mobia Medical
Mobia Medical (MOBI) plans to raise $150 million at a market cap of $549 million. Mobia’s Vivistim Paired Vagus Nerve Stimulation System is the only clinically validated, FDA-approved solution specifically designed for chronic ischemic stroke survivors experiencing moderate to severe upper extremity impairments. This innovative system incorporates an implanted pulse generator and lead that deliver stimulation during functional movement to promote neuroplasticity and support the durable restoration of motor function.
Rare Earths Americas
Rare Earths Americas (REA) is set to raise $50 million at a market cap of $368 million. This exploration-stage mining company focuses on three projects centered around heavy rare earth elements, such as neodymium-praseodymium, dysprosium, and terbium, primarily used in high-performance permanent magnets. Currently, the company has not generated any revenue.
| U.S. IPO Calendar | |||
|---|---|---|---|
| Issuer Business |
Deal Size Market Cap |
Price Range Shares Filed |
Top Bookrunners |
|
HawkEye 360 (HAWK) Herndon, VA |
$400M $2,728M |
$24 – $26 16,000,000 |
Goldman Morgan Stanley |
| Provides space-based radio signals intelligence for defense applications. | |||
|
Rare Earths Americas (REA) Manchester, GA |
$50M $368M |
$17 – $19 2,777,777 |
Cantor Fitz. Stifel |
| Exploration-stage rare earths mining company with projects in Brazil and the US. | |||
|
Suja Life (SUJA) Oceanside, CA |
$200M $871M |
$21 – $24 8,888,889 |
Goldman Jefferies |
| Producer of branded cold-pressed juices and other soft drinks. | |||
|
Mobia Medical (MOBI) Austin, TX |
$150M $549M |
$14 – $16 10,000,000 |
BofA JP Morgan |
| Sells a nerve stimulation device for chronic ischemic stroke. | |||
|
Odyssey Therapeutics (ODTX) Boston, MA |
$225M $821M |
$16 – $18 13,240,000 |
JP Morgan TD Cowen |
| Phase 2 biotech developing precision therapies for autoimmune diseases. | |||
Sign up for a free trial of our premium platform, IPO Pro. To get our IPO calendar in your inbox, register here.
Street research is anticipated for one company, and lock-up periods will soon expire for six others. For details on street research and lock-up expiration dates, consider registering for a free trial of IPO Pro.
Key Takeaways
- Five IPOs are scheduled to launch this week, with potential additions.
- HawkEye 360 is focused on space-based radio signal intelligence.
- Odyssey Therapeutics is developing therapies for autoimmune diseases.
- Suja Life specializes in organic beverages and functional drinks.
- Mobia Medical’s device aims to assist stroke survivors.
- Rare Earths Americas is exploring projects in the rare earth elements sector.
FAQ
What is an IPO?
An IPO, or Initial Public Offering, is the process through which a private company offers shares to the public for the first time, enabling it to raise capital.
Why are companies choosing to go public now?
Companies often go public to secure funding for growth, increase their visibility, and provide liquidity for early investors and employees.
What can investors expect from the upcoming IPOs?
Investors may experience a range of opportunities depending on the companies’ performances and market conditions surrounding their offerings.
How can I invest in these IPOs?
Investing in IPOs typically involves working with a brokerage that allows participation in new offerings; investors should do thorough research before proceeding.
What is the significance of lock-up periods?
Lock-up periods usually restrict insiders from selling their shares for a specific time after an IPO, which helps stabilize the stock’s price shortly after its debut.
